Current Investments
Catalyst Biosciences Inc.
Nassim Usman, South San Francisco, CA, US
http://www.catalystbiosciences.com
Catalyst creates novel catalytic biopharmaceutical products based on engineered human proteases with the aim to to establish protease therapeutics as a therapeutic platform.
Cellerix SA
Eduardo Bravo, Madrid, ES
Cellerix SA is a Madrid-based biopharmaceutical company (Spain) that is developing innovative medicines with advanced clinical programs that are using stem cells of adipocytes origin, for the treatment of various indication including fistulas. Company is in phase III for an autologous approach and in phase II for an allogenic approach.
Cequent Pharmaceuticals Inc.
Peter Parker, Cambridge, MA, US
Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases – from inflammatory diseases to cancer – based on the company’s proprietary technology, TransKingdom RNA interference (tkRNAi) which uses non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. Cequent’s first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease.
Covagen AG
Julian Bertschinger, Zürich, CH
Covagen develops protein therapeutics based on an own protein engineering technology and on Fynomers, a novel protein scaffold.
Cylene Pharmaceuticals Inc.
William Rice, San Diego, CA, US
Cylene uses its proprietary Ribosomal RNA Biosynthesis Inhibition Technology to create small molecule oncology products that act through a validated anti-cancer pathway and target a Protein:DNA complex (Nucleolin:G-Quadruplex) that is amplifi ed in cancer cells, thereby inducing apoptosis in the cancer cells but not normal cells.